Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis
This article was originally published in The Pink Sheet Daily
Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.
You may also be interested in...
Third-party value assessment organization says AbbVie/Neurocrine's elagolix would be cost effective for endometriosis and associated pain, using a placeholder price of $7,000 per year. But the cost would be substantial for health budgets given the broad prevalence of the condition.
Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.
Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.